KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Retained Earnings (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Retained Earnings for 6 consecutive years, with $36.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 580.78% year-over-year to $36.7 million, compared with a TTM value of $36.7 million through Dec 2025, up 580.78%, and an annual FY2025 reading of $36.7 million, up 580.78% over the prior year.
  • Retained Earnings was $36.7 million for Q4 2025 at Recursion Pharmaceuticals, up from -$2.0 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $36.7 million in Q4 2025 and bottomed at -$2.0 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$772.7 million, with a median of -$639.6 million recorded in 2022.
  • The sharpest move saw Retained Earnings plummeted 87.3% in 2021, then soared 580.78% in 2025.
  • Year by year, Retained Earnings stood at -$400.1 million in 2021, then tumbled by 59.86% to -$639.6 million in 2022, then crashed by 36.76% to -$874.6 million in 2023, then surged by 99.13% to -$7.6 million in 2024, then skyrocketed by 580.78% to $36.7 million in 2025.
  • Business Quant data shows Retained Earnings for RXRX at $36.7 million in Q4 2025, -$2.0 billion in Q3 2025, and -$1.8 billion in Q2 2025.